STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Overview of AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.

Core Business Areas

AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.

Research, Development, and Collaborations

At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.

Operational Excellence and Strategic Positioning

AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.

Market Significance and Competitive Landscape

The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.

Scientific Rigor and Clinical Expertise

Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.

Conclusion

Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) announces CEO Thomas Equels' participation in two significant investor conferences. He will join the 'COVID-19: What’s Next in Prevention, Treatment & Diagnostics' panel at the BioFlorida Conference on December 9, 2021, at 1:45 PM EST, and also partake in the CEO Forum later that day. Additionally, Equels is scheduled to speak at the Benzinga All Access event on December 16, 2021, at 11:20 AM EST. These engagements highlight AIM's commitment to addressing urgent health issues, including COVID-19 and cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
conferences
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) reported its third quarter financial results for 2021, revealing a cash position of $53.7 million as of September 30. R&D expenses rose to $2.0 million, while G&A expenses decreased to $1.8 million, with a net loss of $3.8 million. The company is advancing multiple clinical trials for Ampligen, including a planned Phase 2 study for late-stage pancreatic cancer following positive survival data. AIM is also focused on developing treatments for COVID-19-related cognitive issues and has filed two provisional patents regarding Ampligen therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech has submitted an Investigational New Drug (IND) application for its drug Ampligen to the FDA, seeking Fast Track status for a Phase 2 study targeting late-stage pancreatic cancer. The AMP-270 trial will include around 250 participants, comparing Ampligen plus standard care against standard care alone. Early data from a prior study reported a median overall survival increase of 6.7 months for Ampligen-treated patients. AIM's application aims to enhance development and review processes for potential therapies addressing serious medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has released safety data from a Phase 1 clinical study of its drug Ampligen, highlighting its potential as an intranasal treatment for COVID-19. The study involved 40 healthy subjects, showing that Ampligen is generally well tolerated with no severe adverse events reported. Following these positive safety results, AIM is advancing towards a Phase 2a Human Challenge Trial and filing a Pre-Investigational New Drug application with the FDA for further studies. Results for immunological activity are expected in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
-
Rhea-AI Summary

AIM ImmunoTech has finalized the Phase 2 study protocol for Ampligen, targeting late-stage pancreatic cancer. The company plans to submit an IND and apply for Fast Track designation by October 18, 2021. The study will be managed by Amarex Clinical Research, with the Buffett Cancer Center and Erasmus MC as lead sites. Early-access data revealed a significant increase in overall survival (19.2 months) for Ampligen-treated patients compared to a control group (12.5 months). The trial will include approximately 250 subjects and aims to assess Ampligen's efficacy when combined with standard care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
-
Rhea-AI Summary

AIM ImmunoTech Inc. has announced a Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen, targeting intranasal prophylaxis against respiratory viruses. Conducted by hVIVO, the trial is set to enroll 64 healthy participants, who will be exposed to human rhinovirus and influenza A to evaluate Ampligen's efficacy. The study is pending approval from the Oxford Research Ethics Committee, with expectations to start in Q4 2021. A successful trial could position Ampligen as a viable prophylactic against current and future viral threats.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
Rhea-AI Summary

AIM ImmunoTech has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for two Phase 2 studies to evaluate Ampligen’s potential as a treatment for early-onset COVID-19. These randomized, double-blind trials will assess Ampligen as both an intravenous therapy (200 mg) and an intranasal spray (1,250 μg). Preliminary data suggest Ampligen could boost immunity against respiratory viruses and reduce SARS-CoV-2 infectious viral yields by 90%. The company aims to validate its provisional patent for Ampligen, highlighting its significant therapeutic potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
clinical trial covid-19
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) announced a provisional patent application for Ampligen, designed as an early-onset intranasal therapy aimed at enhancing immunity against RNA respiratory viruses, including SARS-CoV-2. The therapy targets viral replication and aims to induce a broader immune response. Upcoming clinical trials will focus on intranasal therapeutic effects and exploratory endpoints to validate Ampligen's potential. AIM’s COVID-19 patent portfolio includes multiple provisional applications for ampligen-related treatments, reflecting its commitment to combat viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has made significant strides in its Phase 2 clinical study of Ampligen for treating Post-COVID-19 Cognitive Dysfunction (PCCD). The U.S. FDA has accepted AIM’s meeting request, facilitating a referral to the Division of Neurology. The trial will include 80 participants receiving either Ampligen or a placebo over 12 weeks. Both AIM CEO Thomas K. Equels and Amarex Clinical Research’s CEO Dr. Kazem Kazempour expressed optimism regarding this regulatory alignment, highlighting the potential for a new treatment addressing cognitive symptoms of Long COVID.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
clinical trial covid-19
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) announced an update on its Phase 2a Human Challenge Trial for its drug Ampligen, targeting intranasal prophylactic therapy against human rhinovirus (HRV-16) and influenza A virus (H3N2). The study protocol was submitted to the Oxford Research Ethics Committee, with a review meeting scheduled for September 24, 2021. The trial plans to enroll 64 participants in a double-blind setup to evaluate Ampligen's efficacy. A successful outcome may position Ampligen as a preventative treatment for various respiratory viruses. AIM is collaborating with hVIVO to finalize a Clinical Trial Agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.0949 as of April 4, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 5.1M.

What is the core focus of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is primarily focused on the research and development of novel therapeutics to treat various forms of cancer, immune-deficiency disorders, and viral diseases.

What are the main therapeutic products developed by AIM ImmunoTech?

The company develops products such as an injectable formulation of natural alpha interferon for certain STDs and Ampligen, a macromolecular RNA-based molecule investigated for cancer, chronic fatigue syndrome, and viral infections.

How does AIM ImmunoTech position itself within the biopharmaceutical industry?

The company positions itself by focusing on specialized therapeutic areas and leveraging robust clinical research and collaborations with renowned international partners to validate its compounds.

What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?

Ampligen plays a key role as a versatile therapeutic candidate that is being evaluated for its efficacy in treating a range of conditions including various cancers, chronic fatigue syndrome, and its potential as a vaccine adjuvant.

How does the company approach clinical research and product development?

AIM ImmunoTech emphasizes rigorous clinical trial methodologies, strategic partnerships, and detailed research protocols to ensure that its therapeutic candidates meet high standards of safety and efficacy.

What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?

Its focused approach on niche therapeutic areas, commitment to innovative clinical research, and strategic international collaborations allow AIM ImmunoTech to address unmet medical needs and differentiate itself within a competitive market.
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

5.09M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA